Efficacy of platinum/pemetrexed combination chemotherapy in ALK-positive non-small cell lung cancer refractory to second-generation ALK inhibitors

BACKGROUND: The current standard initial therapy for advanced ALK-positive non-small cell lung cancer (NSCLC) is a second-generation ALK tyrosine kinase inhibitor (TKI) such as alectinib. The optimal next-line therapy after failure of a second-generation ALK TKI remains to be established; however, s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Oncol
Main Authors: Lin, Jessica J., Schoenfeld, Adam J., Zhu, Viola W., Yeap, Beow Y., Chin, Emily, Rooney, Marguerite, Plodkowski, Andrew J., Digumarthy, Subba R., Dagogo-Jack, Ibiayi, Gainor, Justin F., Ou, Sai-Hong Ignatius, Riely, Gregory J., Shaw, Alice T.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7058505/
https://ncbi.nlm.nih.gov/pubmed/31669591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2019.10.014
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados